260 likes | 269 Views
Understand the clinical significance, management issues, and association of focal C4d deposits in the kidney. Explore guidelines for C4d interpretation, detection of DSA, and biologic explanations for C4d-positive and DSA-negative cases.
E N D
SIGNIFICANCE OF FOCAL C4d DEPOSTIS IN THE KIDNEY P.Randhawa, A. Girnita, A. Zeevi, R. Shapiro, I. Batal, Departments of Pathology, Surgery, University of Pittsburgh
OUTLINE OF TALK • Definition of focal C4d • Clinical significance • Management issues • Occurrence of DSA –ve cases • Association with Dx other than AMR
GUIDELINES FOR C4d INTERPRETATION • Minimum 5 hpf Cortex or medulla (concordant in 75% graft nephrectomy). • Necrotic/scarred area exclude ( intensity) • Linear, circumferential, finely granular • Intensity at least 1+ intensity on FS • HCHO weak stain may be significant
Neg Neg Neg Unknown Unknown ?Pos Pos Pos BANFF 2007 DEFINITION OF C4d STAINING PATTERNS % biopsy area Interpretation according to technique (cortex and medulla) IF IHC • C4d0 Negative: 0% • C4d1 Minimal 1-10% • C4d2 Focal 10-50% • C4d3 Diffuse >50%
: BANFF 2001 MEETING Only C4d + and – categories recognized. Positive staining was defined as bright linear staining along capillary basement membranes typically involving OVER HALF OF SAMPLED peritubular capillaries NUMBER of capillaries expressed as a percentage, rather than SURFACE AREA of biopsy was the defining criterion Racusen et al. Am J Transplant 2003: 3: 708
% CAPILLARY SCORING • % PTC score used in many studies >2001 • Difficult to apply IF (dark field evaluation) • Can not take in account loss of sensitivity of C4d staining on formalin fixed tissue • Underestimates extent of C4d staining in bxs with IFTA & capillary loss
PTC C4d STAINING PATTERNS (106 BX WITH AR & C4d STAIN) Kayler et al. Transplantation 2008; 85: 813
MANAGEMENT OF FOCAL C4d+ BIOPSIES AT PITTSBURGH • Correlate with presence of DSA • Pure Acute AMR with DSA, rising creatinine, get IVIG &/or PP • Treat any concurrent T-cell mediated AR • Assess degree of histologic chronicity
C4d + DSA –VE CASES:Technical Issues • Technical problems with C4d staining -high background, necrotic or scarred area • Technical problems with antibody testing (a) Date (b) Rare antigen not present in testing panel (c) Incorrect HLA Typing of donor HLA (d) Incomplete donor typing (anti-DP, DQ)
DETECTION OF DSA DEPENDS ON SENSITIVITY OF TECHNIQUE • 41 biopsies focal C4d, ELISA PRA screening test for anti-HLA antibody -ve • 11/41= 27% had DSA by Luminex • 7/41 = 17% antibodies to MICA
BIOLOGIC EXPLANATIONS FOR C4d + DSA –VE CASES: • Adsorption of DSA to graft • Non-donor specific antibodies • Non-HLA antibodies • C4d deposition in dx other than AMR
NON-DONOR SPECIFIC HLA ABS • Statistically more AR & worse outcome • Marker for high immune responsiveness • DSA may actually be present but absorbed • Monitor carefully Hourmant et al. JASN2005;16;2804
NON-HLA ANTIBODIES • AECA: anti-endothelial antibodies • Anti-GSTT1 Glutathione S-Transferase T1 • MICA, MICB • AT1R ab: Angio II type I receptor ab • Anti-VIM/ICAM-1 ab assoc GAX in heart • Anti-AGRIN (GBM) ab associated cg • Anti-HY ab products of Y chromosome
POTENTIAL TARGETS OF AECA • MHC antigens • ABO antigens • AT1R receptors • MICA (Mhc class I related Chain Ag) • Other unknown polymorphic ags
PROBLEMS WITH AECA STUDIES • Most assays do not attempt to define ag. • Studies cross sectional: cause & effect? • Some AECA definitely 20 vascular injury - due to rejection (intimal arteritis) - viral infection (CMV)
AECA & ANTI-HLA CAN CO-EXIST • FCM assay XM-ONE Kit PBL endoth progenitors -35/147 (24%) pre-tx sera had donor reactive ab -Acute rejection 16/35 (46%) vs 13/112 (12%); -6/16 C4d +, ALL had confounding HLA ab Breimer et al. Txn 2008; 87: 549:
SOME AEC ASSAYS DO MEASURE COMPLEMENT FIXING AB • EUROIMMUN indirect IF reagent kit and HUVEC deposited on BIOCHIPs • AECA in 13/47 patients vascular rejection • 6/13 C4d+ (46%); 1/6 anti-HLA + • Plasma cell infiltrate 54% AEC-AR vs 12%no AR • Overall 1 yr graft loss 46% AEC vs 19 % no AEC Sun et al. CJASN 2008; 3; 1479
ANTI-GLUTATHIONE S-TRANSFERASE T1 ANTIBODIES • Donor has GSTT1 gene, recipient does not • Incidence of GSTT1 mismatch ~ 20% • Initial associative studies severe liver dysfunction • Ktx: one study reported 4 cases of CHRONIC AMR with C4d in peritubular capillaries • 1 case report acute AMR is also available Aguilera et al NDT 2008; 23; 1393
BANFF CATEGORIES OTHER THAN AMR WITH C4d DEPOSITS • Recurrent antiGBM • Post-tx IgA 16/66 PTC Cho et al Clin Tx 2007:21:159 • Colvin: USCAP 38% Denovo 17% rMGN • Feucht 2001: 6/10 GN 11/19 ATN • Feucht 2003: ATN C3d, not C4d Feucht et al. KI 2001:5934; AJT 2003:3:646
C4d DESCRIBED IN NATIVE KIDNEY DISEASES • Lupus nephritis (31/455, D) • -Li et al. Lupus 2007:16:875 • - granular, EM immune complex deposits • 2/2 Bacterial endocarditis GN • Scleroderma renal crisis • -diffuse 1/11, focal 3/11 • Two donor, 1 DIC kidney (F) • C activation multiple paths
SUMMARY • Focal C4d PTC <50% surface area • Staining pattern affected by tissue fixation • Significance: correlate histology & DSA • % patients with DSA intermediate • DSA–ve: technical issues, non-HLA abs, diseases other than AMR